Isomorphic Labs secures $2.1 billion to advance AI-designed drug development, partnering with major pharmaceutical companies ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

These high capital-intensity, asset-heavy companies offer a proven hedge against 'Magnificent Seven' volatility "Anti-AI" stocks are a contrarian bet that the market's tech-fueled rally will be ...

Recursion Pharmaceuticals (RXRX) has been in focus after fresh clinical updates on REC-4881 and REC-1245, along with ongoing FDA discussions for a potential registrational pathway, drew attention away ...

Recursion Pharmaceuticals (NasdaqGS:RXRX) reported key clinical milestones across its AI-driven pipeline, including positive early data for REC-1245. The company initiated a new Phase 1 trial for ...

Detailed price information for Kissei Pharm CO Ltd (KSPHF) from The Globe and Mail including charting and trades.

Earlier this year, Recursion Pharmaceuticals Inc RXRX initiated discussions with the FDA for the design of a registrational ...

Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) is one of the best AI stocks under $50 to buy right now. On May 6, Recursion ...

Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.5 per share a year ago. These ...

Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid ...

Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than ...

SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Recursion Pharmaceuticals Inc. (RXRX) on Wednesday reported a loss of $117.5 million in its first quarter. The Salt Lake City-based company said it had a ...